注册以创建品种、
财经事件和所关注作者内容的提醒
免费注册 已有账户? 登录
Denali Therapeutics Inc是一家生物制药公司。该公司专注于发现和开发针对神经退行性疾病患者的疗法,包括阿尔茨海默病、帕金森病、肌萎缩侧索硬化症(ALS)等。该公司的临床项目包括富含亮氨酸的重复激酶2(LRRK2)抑制剂项目、真核起始因子2 B(EIF2B)激活剂项目、酶转运载体:艾杜糖酸2-硫酸酯酶(ETV:IDS)项目、受体相互作用的丝氨酸/苏氨酸蛋白激酶1(RIPK1)抑制剂项目和次级非中枢神经系统(CNS)渗透RIPK1抑制剂。该公司设计其候选产品以穿过血脑屏障(BBB),并直接作用于大脑。其项目管线包括大约15个基于其电视技术的项目,包括领先的项目ETV:IDS(DNL310)。其产品线包括DNL151、DNL593(PTV:PGRN)、DNL126(ETV:SGSH)、DNL788、DNL343和DNL758。
名称 | 年龄 | 任期 | 标题 |
---|---|---|---|
Jay T. Flatley | 71 | 2015 | Independent Director |
David P. Schenkein | 67 | 2015 | Independent Director |
David M. Holtzman | - | 2020 | Member of Scientific Advisory Board |
Peter S. Klein | 62 | 2018 | Independent Director |
Kevan M. Shokat | - | 2023 | Member of Scientific Advisory Board |
Stacie Weninger | - | 2021 | Member of Scientific Advisory Board |
Henrik Zetterberg | - | 2019 | Member of Scientific Advisory Board |
Eric M. Reiman | - | - | Member of Scientific Advisory Board |
Melissa A. Starovasnik | 58 | 2021 | Member of Scientific Advisory Board |
Nancy A. Thornberry | 67 | 2021 | Independent Director |
Marc Tessier-Lavigne | 64 | 2015 | Co-Founder & Independent Director |
Vicki L. Sato | 75 | 2015 | Independent Chairperson |
Ryan J. Watts | 48 | 2015 | Co-Founder, President, CEO & Director |
Steve Edward Krognes | 56 | 2015 | Director |
Scott A. Biller | 68 | - | Member of Scientific Advisory Board |
Jennifer E. Cook | 58 | 2018 | Independent Director |
Erik Harris | 53 | 2022 | Independent Director |
确定屏蔽%USER_NAME%?
如果屏蔽,您和%USER_NAME%都无法看到相互在Investing.com上发布的信息。
%USER_NAME%已成功添加至屏蔽列表
由于您刚刚取消屏蔽此人,因此必须等待48小时才能重新屏蔽。
您举报该评论的原因为:
谢谢您!
您的举报将会被发送到管理员进行审核